Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arcellx, Inc. - Common Stock (NQ: ACLX )

53.62 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 53.62
Bid (Size) 21.56 (1)
Ask (Size) 56.70 (6)
Prev. Close 53.62
Today's Range 53.62 - 53.62
52wk Range 30.74 - 75.10
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations For Arcellx's Future
Via Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-4.51%
-4.51%
1 Month
+3.81%
+3.81%
3 Month
-10.51%
-10.51%
6 Month
+1.90%
+1.90%
1 Year
+25.90%
+25.90%

More News

Read More
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Arcellx, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Arcellx Provides First Quarter 2024 Financial Results
From Arcellx, Inc.
Via Business Wire
Peering Into Arcellx's Recent Short Interest
Via Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
Via Benzinga
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Via InvestorPlace
Arcellx to Participate in Two Upcoming Investor Conferences
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Arcellx, Inc.
Via Business Wire
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
Via InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
Via Talk Markets
Topics Stocks
Exposures US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Via InvestorPlace
Exposures Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Via Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
Via InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Via Benzinga
Chart Of The Day: Arcellx - Reimagining Cell Therapy
Via Talk Markets
3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
Via Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.